Physician profile
Audrey Alana Strock
NPI 1356561161
$498,825.38
in general payments reported to CMS, 2019-2025
18 companies · $178K in 2025
The $178K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25K · 2022: $37K · 2023: $125K · 2024: $134K · 2025: $178K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $346K · Travel and Lodging: $66K · Honoraria: $13K · Food and Beverage: $10K · Consulting Fee: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $346,135.00 |
| Travel and Lodging | $65,660.07 |
| Honoraria | $13,001.00 |
| Food and Beverage | $10,095.11 |
| Consulting Fee | $1,072.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471,979.45 | 2021-2025 | |
| Axsome Therapeutics, INC. | $16,176.31 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $6,113.20 | 2025 | Fanapt |
| Corium, LLC | $1,402.25 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $687.53 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $639.31 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $621.81 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $335.34 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $202.62 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $180.26 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $152.88 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $71.49 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $69.59 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $67.53 | 2023-2024 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $52.76 | 2024-2025 | Relexxii |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.01 | 2023-2025 | Spravato, Invega Trinza, Invega |
| E.R. Squibb & Sons, L.L.C. | $16.62 | 2025 | Cobenfy |
| Tris Pharma INC | $14.42 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Strock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.